Back to discover
Drug

Technetium

In clinical development
Emerging researchLate-stage development
1
Research papers
2
Active clinical trials

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Technetium
RxNorm CUI
2571856

Clinical trials

4 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
4
registered trials across all phases
LATEST COMPLETION 2012
2
Active studies
2
Recruiting
4
Late-stage (III+)
2
Completed
PHASE DISTRIBUTIONn = 4
Phase 32Phase 41Phase N / A1

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes3
Neoplasms1Single-Chain Antibodies1Single-Domain Antibodies1
Journals, researchers & institutions
Top journals
  • Frontiers in immunology1
Leading researchers
  • Awad RM1
  • Breckpot K1
  • Ceuppens H1
  • De Groof TWM1
  • de Mey W1
  • Devoogdt N1
  • Ertveldt T1
  • Meeus F1
Leading institutions
free-text, unnormalised
  • Laboratory for Cellular and Molecular Immunology (CMIM)1
  • Laboratory for Molecular and Cellular Therapy (LMCT)1
  • Laboratory of Molecular Imaging and Therapy (MITH)1
  • Vlaams Instituut voor Biotechnologie (VIB) Center for Inflammation Research1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials